Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

Bastian von Tresckow, Michelle Fanale, Kirit M. Ardeshna, Robert Chen, Julia Meissner, Franck Morschhauser, Craig Moskowitz, Pier Luigi Zinzani, Hilde Giezek, Arun Balakumaran, Thao T. Vo, Monika Raut, Pauline Brice

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were ≥90% at week 12 and ≥70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts. Clinicaltrials.gov identifier: NCT02453594.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Hodgkin Disease
Quality of Life
Stem Cell Transplantation
Patient Safety
Visual Analog Scale
Health Status
Compliance
Lymphoma
Transplantation
Organizations
Drug Therapy
Patient Reported Outcome Measures
pembrolizumab
Surveys and Questionnaires
Health
Research
cAC10-vcMMAE
Neoplasms
Therapeutics

Keywords

  • Classical Hodgkin lymphoma
  • health-related quality-of-life
  • KEYNOTE-087
  • patient-reported outcomes
  • pembrolizumab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. / von Tresckow, Bastian; Fanale, Michelle; Ardeshna, Kirit M.; Chen, Robert; Meissner, Julia; Morschhauser, Franck; Moskowitz, Craig; Zinzani, Pier Luigi; Giezek, Hilde; Balakumaran, Arun; Vo, Thao T.; Raut, Monika; Brice, Pauline.

In: Leukemia and Lymphoma, 01.01.2019.

Research output: Contribution to journalArticle

von Tresckow, B, Fanale, M, Ardeshna, KM, Chen, R, Meissner, J, Morschhauser, F, Moskowitz, C, Zinzani, PL, Giezek, H, Balakumaran, A, Vo, TT, Raut, M & Brice, P 2019, 'Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma', Leukemia and Lymphoma. https://doi.org/10.1080/10428194.2019.1602262
von Tresckow, Bastian ; Fanale, Michelle ; Ardeshna, Kirit M. ; Chen, Robert ; Meissner, Julia ; Morschhauser, Franck ; Moskowitz, Craig ; Zinzani, Pier Luigi ; Giezek, Hilde ; Balakumaran, Arun ; Vo, Thao T. ; Raut, Monika ; Brice, Pauline. / Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. In: Leukemia and Lymphoma. 2019.
@article{4b8a4083f3cc4e2da20be437a5aeba0f,
title = "Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma",
abstract = "In KEYNOTE-087, pembrolizumab had a 69{\%} overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were ≥90{\%} at week 12 and ≥70{\%} at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts. Clinicaltrials.gov identifier: NCT02453594.",
keywords = "Classical Hodgkin lymphoma, health-related quality-of-life, KEYNOTE-087, patient-reported outcomes, pembrolizumab",
author = "{von Tresckow}, Bastian and Michelle Fanale and Ardeshna, {Kirit M.} and Robert Chen and Julia Meissner and Franck Morschhauser and Craig Moskowitz and Zinzani, {Pier Luigi} and Hilde Giezek and Arun Balakumaran and Vo, {Thao T.} and Monika Raut and Pauline Brice",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/10428194.2019.1602262",
language = "English (US)",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

AU - von Tresckow, Bastian

AU - Fanale, Michelle

AU - Ardeshna, Kirit M.

AU - Chen, Robert

AU - Meissner, Julia

AU - Morschhauser, Franck

AU - Moskowitz, Craig

AU - Zinzani, Pier Luigi

AU - Giezek, Hilde

AU - Balakumaran, Arun

AU - Vo, Thao T.

AU - Raut, Monika

AU - Brice, Pauline

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were ≥90% at week 12 and ≥70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts. Clinicaltrials.gov identifier: NCT02453594.

AB - In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were ≥90% at week 12 and ≥70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts. Clinicaltrials.gov identifier: NCT02453594.

KW - Classical Hodgkin lymphoma

KW - health-related quality-of-life

KW - KEYNOTE-087

KW - patient-reported outcomes

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85064761416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064761416&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1602262

DO - 10.1080/10428194.2019.1602262

M3 - Article

C2 - 31012356

AN - SCOPUS:85064761416

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -